Ibrutinib
About
Therapy type: Targeted therapy
Therapy strategy: BTK inhibition
Mappings
NCI Thesaurus: Ibrutinib (ncit:C81934)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| HSE (1) | TP53 somatic variants | Chronic Lymphocytic Leukemia | Ibrutinib | |
| HSE (1) | TP53 deletion | Chronic Lymphocytic Leukemia | Ibrutinib | |
| FDA (1) HSE (1) | 17p deletion | Chronic Lymphocytic Leukemia | Ibrutinib |